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Abstract
Background: In general, opioids that induce the recycling of µ-opioid receptors (MORs) promote
little desensitization, although morphine is one exception to this rule. While morphine fails to
provoke significant internalization of MORs in cultured cells, it does stimulate profound
desensitization. In contrast, morphine does promote some internalization of MORs in neurons
although this does not prevent this opioid from inducing strong antinociceptive tolerance.
Results: In neurons, morphine stimulates the long-lasting transfer of MOR-activated Gα subunits
to proteins of the RGS-R7 and RGS-Rz subfamilies. We investigated the influence of this regulatory
process on the capacity of morphine to promote desensitization and its association with MOR
recycling in the mature nervous system. In parallel, we also studied the effects of [D-Ala2, N-
MePhe4, Gly-ol5] encephalin (DAMGO), a potent inducer of MOR internalization that promotes
little tolerance. We observed that the initial exposure to icv morphine caused no significant
internalization of MORs but rather, a fraction of the Gα subunits was stably transferred to RGS
proteins in a time-dependent manner. As a result, the antinociception produced by a second dose
of morphine administered 6 h after the first was weaker. However, this opioid now stimulated the
phosphorylation, internalization and recycling of MORs, and further exposure to morphine
promoted little tolerance to this moderate antinociception. In contrast, the initial dose of DAMGO
stimulated intense phosphorylation and internalization of the MORs associated with a transient
transfer of Gα subunits to the RGS proteins, recovering MOR control shortly after the effects of
the opioid had ceased. Accordingly, the recycled MORs re-established their association with G
proteins and the neurons were rapidly resensitized to DAMGO.
Conclusion: In the nervous system, morphine induces a strong desensitization before promoting
the phosphorylation and recycling of MORs. The long-term sequestering of morphine-activated Gα
subunits by certain RGS proteins reduces the responses to this opioid in neurons. This
phenomenon probably increases free Gβγ dimers in the receptor environment and leads to GRK
phosphorylation and internalization of the MORs. Although, the internalization of the MORs
permits the transfer of opioid-activated Gα subunits to the RGSZ2 proteins, it interferes with the
stabilization of this regulatory process and recycled MORs recover the control on these Gα
subunits and opioid tolerance develops slowly.
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In the nervous system, G protein-coupled Mu-opioid
receptors (MORs) drive the initial steps of both the posi-
tive effects of opioids (i.e. relief of intense inflammatory
pain) and their addictive effects. A desensitization to mor-
phine that last for several days can occur within hours of
administering an appropriate single dose [1] and this is
accompanied by some degree of physical dependence [2].
Both single-dose tolerance and that promoted by repeated
exposure to morphine seem to share some certain molec-
ular mechanisms. Indeed, both situations can be modu-
lated by similar pharmacological treatments [3].
The inactivation of G protein-coupled receptors (GPCRs)
commences with the activation of G proteins upon ago-
nist binding, which in turn produces the segregation of
GαGTP subunits from the Gβγ dimers. The increased pool
of free Gβγ dimers facilitates their binding to the G pro-
tein-coupled receptor kinases (GRK) and hence, the inter-
action between these kinases and the receptors. In this
way, the agonist-bound receptors become a GRK sub-
strate, leading to the phosphorylation of critical cytosolic
serine/threonine residues in the receptor. This modifica-
tion enables β-arrestin to bind to these residues if the ago-
nist remains bound to the receptor [4], setting in motion
an endocytic process. Recycling of these internalized
receptors to the plasma membrane must occur for the
response to agonists to be more rapidly recovered [5].
However, the proteolytic degradation of the endocytosed
receptors in lysosomes promotes the down-regulation of
the number of surface receptors and brings about a
decreased response to the agonist [6].
The phosphorylation of serine 375 in the C terminus of
the MOR accompanies the agonist-driven internalization
process [7,8]. Although the endocytosed MORs can be
sorted into lysosomes, the majority recycle rapidly to the
plasma membrane through a signal-dependent process
[9]. Interestingly, the efficiency of opioid agonists to stim-
ulate MOR endocytosis differs and this is related to their
capacity to promote GRK-dependent phosphorylation of
cytosolic residues in the MOR [10,11]. It is believed that
morphine induces a high degree of desensitization
because it fails to provoke significant phosphorylation
and internalization of the MORs [12]. Therefore, opioid
agonists that efficiently promote MOR endocytosis would
not be associated with high opioid tolerance [13].
It is evident that studies on cells have revealed some criti-
cal mechanisms that control the activity of cell surface
MORs. However, there is still limited information on the
molecular processes that are involved in regulating MORs
in the mature nervous system. In this respect, opioid ago-
nists such as etorphine and DAMGO have been shown
through immunofluorescence techniques to produce
MOR internalization in brain, spinal cord and dorsal root
ganglia neurons [14-16]. Notably, and in contrast to what
is observed in cultured cells, morphine produces some
membrane trafficking of the MORs in dendrites of nucleus
accumbens neurons and more extensive MOR internaliza-
tion in embryonic striatal neurons and ganglia neurons
[17-19]. Therefore, although the essential mechanisms of
MOR regulation established in cultured cells could apply
to neurons, these highly specialized cells also have their
own rules to control GPCR function. For example, the
expression of certain RGS proteins such as members of
RGSZ1, RGSZ2, RGS-R7 subfamily, and of Gαz subunits,
is virtually restricted to nervous tissue, and these proteins
certainly influence the regulation of neural MORs [20].
We set out here to evaluate the implication of the phos-
phorylation, internalization and recycling of MORs on the
desensitizing capacity of morphine and DAMGO in the
murine nervous system. We show that tolerance to intrac-
erebroventricular (icv) morphine was induced by the sta-
ble transfer of part of the MOR-activated Gα subunits to
RGS proteins of the R7 and Rz subfamilies [21,22],
thereby increasing the pool of free Gβγ dimers in the
receptor environment. Afterwards, subsequent doses or
prolonged exposure to this opioid promoted the GRK
phosphorylation of MORs and their internalization and
recycling. In these circumstances, the effects that remain
after the first dose now desensitized at a much slower rate.
DAMGO evaded the first part of this process directly pro-
ducing the efficient Ser375 phosphorylation and recycling
of MORs, which was accompanied by low tolerance to its
effects. However, repeated exposure to these opioids led
to the incomplete recycling of the MORs and strong toler-
ance developed.
Results
Desensitizing capacity of morphine and how it is 
influenced by the interval between doses
The alleviation of intense inflammatory pain is the most
positive effect of opioids and therefore, we analyzed the
development of antinociceptive tolerance in the light of
the changes that affect the MORs. Upon icv administra-
tion, opioids gain access to periventricular areas impli-
cated in the control of ascending pro-nociceptive
information. The analgesic test involves the application of
a noxious thermal stimulus to promote a flick of the
mouse tail, and the administration of analgesic drugs
increases the time that elapses between these two events.
Whereas, this motor response is still observed in the inter-
collicular decerebrated animal, stimulus of much higher
intensity are needed to evoke this behavior in the spinal
animal. Therefore, this response comprises a spinal reflex
which is under a facilitatory drive from the brain stem and
the MORs in the periaqueductal grey matter (PAG) playPage 2 of 13
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administered by the icv route [23].
The analysis of MORs in the PAG reveals a series of iso-
forms that are produced by the alternative splicing of the
murine MOR [24], and also by N-glycosylation of these
variants [25]. Accordingly, these MORs are generally
observed at apparent masses of 50–65 kDa, 80–100 kDa
and even higher. In our experimental paradigm, icv
administration of 10 nmol morphine produced time-
dependent antinociception that peaked 30 min after opi-
oid administration and that reached about 80% of the
maximum effect measurable in this test. This analgesia
had ceased 3 h after the administration of the opioid (Fig.
1). During the time-course of the initial dose of morphine
and beyond, the surface levels of MORs remained practi-
cally unchanged and the serine 375 displayed moderate
phosphorylation. Accordingly, no substantial internaliza-
tion of MORs was produced and only a small signal could
be immunoprecipitated from the supernatant (Fig. 1).
The induction of single-dose tolerance is a time-depend-
ent phenomenon that develops after the first exposure of
the animals to the opioids and it can be impaired by
inhibitors of protein synthesis [26]. Thus, we determined
the interval between morphine administrations required
to detect this tolerance. When the initial dose of 10 nmol
morphine was repeated 3 h after the first dose, the analge-
sic effect was comparable to that of the first [27]. How-
ever, at intervals of 6 h or 24 h the analgesia produced by
morphine was much weaker (Fig. 2). The antinociceptive
potency of the initial dose of morphine was recovered
after 4 to 5 days [28]. Interestingly, this time frame is that
required to recover the analgesic effects from the action of
β-funaltrexamine, an irreversible antagonist of MORs
[29]. These observations suggest that new synthesis of
MORs is required to overcome the tolerance that follows
an acute dose of morphine.
Phosphorylation and internalization of MORs stimulated 
by two consecutive administrations of morphine
When a second dose of morphine was icv-injected 6 h
after the first, antinociceptive tolerance was accompanied
by a reduction in the amount of MORs in the membrane
coupled to an increase in the proportion of intracellular
receptors. Moreover, whilst the first dose of morphine
caused moderate serine375 phosphorylation of MORs,
this second dose promoted notable phosphorylation of
the receptors that could be detected both at the surface as
well as in the internalized MORs (Fig. 2). The Ser-phos-
phorylated MORs could be detected in the plasma mem-
brane even 24 h after of administration of this second
dose of morphine. Therefore, the repeated administration
of morphine promoted both phosphorylation and inter-
nalization of MORs, and now the decrease of surface
Regulation of neural MORs by icv administration of an analgesic dose of morphineFig re 1
Regulation of neural MORs by icv administration of an anal-
gesic dose of morphine. Insert: The mice were icv-injected with 10 
nmol morphine and antinociception was determined by the warm 
water (52°C) tail-flick test at various time intervals post-injection. 
Antinociception was expressed as a percentage of the maximum pos-
sible effect after setting a cut-off time of 10 seconds. The values 
shown are the mean ± SEM from groups of 10–15 mice. Effect of mor-
phine treatment on internalization and phosphorylation of the C ter-
minal Ser375 of MOR. The PAG synaptosomes (P2) and supernatant 
(S3) were obtained at various intervals post-morphine administration. 
For each time point studied the PAG structures from 6 to 8 mice 
were pooled. To reduce the risk of interference with signals from 
proteins other than the MORs, the study of these receptors and their 
Ser375 phosphorylation was performed by immunoprecipitation after 
releasing the associated proteins by SDS solubilization (denaturing 
conditions, see Methods). In order to detect additional protein bands, 
the areas inside the rectangles were overexposed. The densitometric 
immunosignals associated with the 55–65 kDa band (average optical 
density of the pixels within the object area/mm2; Quantity One Soft-
ware, BioRad) were normalized to those obtained probing the anti-
MOR IgGs hc (heavy chain) with the appropriate secondary antibody. 
These IgGs were detached from the immunoprecipitated MORs and 
processed in parallel gels/blots (see Methods). Each bar is the mean ± 
SEM of three assays performed on PAG samples obtained from inde-
pendent groups of mice. The data are expressed relative to the levels 
observed for the control group (attributed an arbitrary value of 1).
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receptors. After this second dose of the opioid, further
doses morphine spaced at intervals of 24 h produced com-
parable peak analgesic effects. Thus, after promoting a
high tolerance then morphine is able to support the recy-
cling of the MORs, and then tolerance to this abated effect
develops at a slow rate. However, the recycling of MORs
receptors seems to be only partial, and reductions in the
intervals between consecutive doses could augment anti-
nociceptive desensitization.
DAMGO promotes Ser375 phosphorylation and 
internalization of MORs in mature neurons
The maximal effect of an icv dose of 200 pmol DAMGO
was similar to that with 10 nmol morphine, producing
about 80% of the MPE. However, the analgesic potency of
a second dose of DAMGO was maintained when injected
6 h after the first. Only when this interval increased to 24
h was a moderate decrease in the effects of this dose
observed (Fig. 3). In contrast to morphine, the initial dose
of DAMGO stimulated strong Ser375 phosphorylation
and internalization of MORs in PAG neurons. However,
an important part of the internalized receptor recycled to
the plasma membrane within 3 h of the administration of
DAMGO when its analgesic effects had ceased (Fig. 3).
While the internalized MORs were no associated with
Gαi2 or Gβ1/2 subunits, they did co-precipitate with β-
arrestin2 and C-Raf. This observation suggests that the
internalized MORs regulate β-arrestin2-dependent path-
ways in these neurons [4]. Thus, our results are in agree-
ment with those describing some internalization of MORs
in the adult rodent brain as a consequence of systemic
administration of acute doses of etorphine (DAMGO)
and the failure of an acute morphine administration to
provoke a detectable loss of these receptors [14]. Moreo-
ver, our observations in PAG neurons are comparable
with those with DAMGO in HEK 293 cells expressing
MORs. In this model DAMGO produces the robust Ser375
phosphorylation and internalization of MORs [7,8], and
its removal facilitated the recycling of MORs to the plasma
membrane and the recovery of the sensitivity to the ago-
nist.
Desensitization of MORs after repeated administrations of 
morphine and DAMGO
The differences observed in the capacity of opioids to pro-
duce desensitization have been attributed to their intrinsic
efficacy. This idea assumes that DAMGO activates only a
fraction of the MORs required for morphine to produce
comparable analgesic effects, thereby promoting much
lower tolerance. However, DAMGO could also stimulate
antinociceptive tolerance by reducing the number of
plasma membrane MORs. To test this possibility we ana-
lyzed the capacity of DAMGO and morphine to produce
tolerance when a more demanding administration proto-
Single-dose tolerance induced by morphine: influence of the interval betwe n dosesFigure 2
Single-dose tolerance induced by morphine: influ-
ence of the interval between doses. Insert: Left panel, 
the mice were icv-injected with 10 nmol morphine and after 
the analgesic effect had ceased, desensitization was evaluated 
by icv-injection of a second and identical dose of this opioid 
at different time intervals. Right panel, the animals received 
several icv-injections of 10 nmol morphine spaced 6 h, 24 h, 
48 h and 72 h from the first, and antinociception was deter-
mined in the tail-flick test at its peak effect 30 min after each 
injection. Values shown are the mean ± SEM from groups of 
8–12 mice. *Statistically significant with respect to the con-
trol (First dose) group; ANOVA, Student-Newman-Keuls 
test (SigmaStat, SPSS Science Software, Erkrath, Germany). 
Significance was set at P < 0.05. The internalization and 
Ser375 phosphorylation of the MORs was studied after 
administration of a second dose of 10 nmol morphine 6 h 
after the first. For further details see Fig. 1 and Results.
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Molecular Pain 2007, 3:19 http://www.molecularpain.com/content/3/1/19col was used. Morphine and related opioids provoke a
profound desensitization of their analgesic effects when
three consecutive doses are icv-injected into mice at 3 h
intervals [27]. Unfortunately, this protocol also produced
desensitization to the analgesic effects of DAMGO, and
the second and third consecutive doses increased the loss
of surface receptors, thereby producing desensitization to
the analgesic response to this opioid (Fig. 4). Indeed, the
successive administrations of morphine also slowly
diminished the density of cell surface MORs (not shown).
The decrease in surface MORs correlated with an increase
in the internalized MORs. While the MORs recycle rap-
idly, a proportion of the internalized MORs undergoes
endocytic sorting to lysosomes and thus, proteolytic deg-
radation [8,9]. The subcellular fractionation of PAG syn-
aptosomes revealed that 30 min after the initial icv-
injection of DAMGO, the internalized MORs were
detected in the early endosome and the recycling endo-
some fractions. However, after four consecutive doses
administered at 3 h intervals, the internalized receptors
accumulated and could be also detected in the late endo-
some/lysosome fraction for their destruction (Fig. 4).
The MORs in the spinal cord play an important role in
development of tolerance induced by systemically admin-
istered opioids. Thus, we analyzed these receptors during
the development of tolerance to morphine administered
subcutaneously by implantation of oily morphine pellets.
The morphine released from this suspension reaches lev-
els of 10–13 nmol per mL of serum and of about 10 nmol
per g of wet brain between 3 h and 12 h [30]. In the hour
that followed the implantation of the morphine suspen-
sion, the mice exhibited an analgesic response that
reached the test cut-off time of 10 s. Subsequently, the
mice developed rapid tolerance to this effect which was
almost absent 12 h later (Fig. 5). The continuous admin-
istration of morphine increased both Ser375-phosphor-
ylation and loss of surface MORs in the dorsal horn of the
spinal cord. These changes were rapidly observed after the
chronic morphine treatment commenced and persisted
over the following 2 days. The reductions were more
intense for the MORs that corresponded to protein bands
of 75 and 100 kDa. It has been reported that these MOR
species are rapidly degraded by the proteosome in HEK
293 cells [31] and our observations suggest a similar situ-
ation in spinal neurons. Therefore, the continuous pres-
ence of morphine in the receptor environment rapidly
shifted the system from the uncoupling of the MORs from
the regulated Gα subunits to the phase where GRKs gain
access to MORs and promote Ser375 phosphorylation,
resulting in the internalization of these receptors. This sit-
uation would be comparable to the internalization of
MORs observed in the presence of elevated concentrations
of morphine in dissociated primary cultures of rat embry-
Regulation of neural MOR phosphorylation and internaliza-tion by DAMGOFig re 3
Regulation of neural MOR phosphorylation and inter-
nalization by DAMGO. Insert: The mice were icv-injected 
with 200 pmol DAMGO and antinociception was determined 
by the warm water (52°C) tail-flick test at various time inter-
vals post-injection. The desensitization produced by the 
priming dose of DAMGO was evaluated injecting a second 
and identical dose of this opioid at various intervals after the 
first dose. *Statistically significant with respect to the control 
(First dose) group; ANOVA, Student-Newman-Keuls test 
(SigmaStat, SPSS Science Software, Erkrath, Germany). Signif-
icance was set at P < 0.05. Details as in Figs. 1 & 2. The phos-
phorylation and internalization of MORs was also evaluated 
after administering the first dose of DAMGO. The internal-
ized MORs co-precipitated β-arrestin-2 (β-ARR2) and C-Raf 
but not Gαi2 or Gβ1/2 proteins. For further details see Fig. 1 
and Results.
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The repeated administration of DAMGO promotes incomplete recycling of internalized MORsFigu e 4
The repeated administration of DAMGO promotes incomplete recycling of internalized MORs. Insert: Groups of 
mice were icv-injected with three successive doses of 10 nmol morphine or 200 pmol DAMGO spaced 3 h apart, plus a fourth 
dose given 24 h after the first. Antinociception was determined by the warm water (52°C) tail-flick test at various time inter-
vals post-injection. Details as in the Figs. 1 & 2. The mice were killed 3 h after the first, the second or the third dose of 
DAMGO and the MORs were immunoprecipitated under denaturing conditions from the P2 (membrane) and S3 (internalized) 
preparations. Mice that had received four doses of DAMGO were killed 30 min later and the PAG S3 fraction was subjected to 
subcellular fractionation and the presence of MOR was determined. Subcellular markers: EEA1 (early endosome antigen 1; BD 
610456), Rab4 (BD 610888), Rab5 (BD 610281), Rab 11 (BD 610656), Lamp-1 (lysosomal-associated membrane protein 1; BD 
611043).For further details see Methods.
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Molecular Pain 2007, 3:19 http://www.molecularpain.com/content/3/1/19onic striatal neurons [18] or mouse dorsal root ganglia
neurons [19].
The coupling of plasma membrane MORs to G proteins 
reduces tolerance to opioid effects
The initial dose of morphine promoted moderate phos-
phorylation of Ser375 and little or no internalization of
the MORs. However, it did alter the association of plasma
membrane MORs with Gα subunits ([21], present work).
Notably, the co-precipitation of these receptors with Gαi2
subunits was greatly diminished and only partially recov-
ered 24 h later. Thus, the morphine-activated Gα subunits
seem to have been permanently transferred to other com-
partment. Here, the RGS9 and RGSZ2 play a relevant role
(Fig. 6) [21,22]. This reduction of MOR-regulated trans-
duction brought about a substantial decrease in the anti-
nociceptive activity of the subsequent doses of the opioid.
Notably, after 6 h the subsequent administration of mor-
phine promoted both phosphorylation and internaliza-
tion of MORs. A good correlation was now observed
between the decreases in surface MORs and the corre-
sponding increase in the internalized pool, as well as with
changes in their association with Gαi2 subunits (Figs. 6
&7). In these circumstances, the MORs in the membrane
activated the Gα subunits that remained after the first
dose of morphine but recovered their control after the
effects of morphine had ceased. During the time-course of
the effects of DAMGO, the Gα subunits underwent a tran-
sient transfer to RGSZ2 proteins and later, the recycled
MORs in the plasma membrane recovered control over
these G proteins and the response to DAMGO was resen-
sitized (Figs. 3 &6). The results indicate that endocytosis
and recycling of MORs diminished the permanent transfer
(sequestering) of Gα subunits to RGS proteins, in this way
reducing the tolerance to the effects of subsequent admin-
istrations of the opioids [11-13,32]. This was observed for
DAMGO (Fig. 3) and for a second dose of morphine,
which now promoted low tolerance to the effects of addi-
tional doses (Fig. 2).
Discussion
The interaction of morphine with neural MORs is the ini-
tial step, both in the development of tolerance to this opi-
oid and towards physical dependence. By analyzing
MORs during the time-course of opioid antinociception,
new aspects of the mechanisms that control these G-
receptors in nervous tissue were revealed. The initial expo-
sure to DAMGO or morphine brought about changes at
the MOR level that compared satisfactorily with those
described in cultured cells. In both systems, DAMGO pro-
duces robust Ser375 phosphorylation and internalization
of the MORs whereas in contrast, morphine only weakly
induces these processes. In addition, following the
removal of DAMGO the MORs recycle back to the cell
membrane resensitizing the response to the opioid. How-
ever, on removal of morphine the cells remain desensi-
tized and exhibit cross-tolerance to DAMGO. Therefore,
while DAMGO produces low tolerance to the effects of
subsequent opioid administration, morphine yields a
high tolerance. Nevertheless, in mature neurons and in
contrast to what might be expected if the MORs were to
resensitize on withdrawal of the agonists, a second dose of
DAMGO had a weaker analgesic effect after an interval of
Development of tolerance to sustained morphine treatment: changes in phosphorylation and urface presenc  of spinal MORsFigur  5
Development of tolerance to sustained morphine 
treatment: changes in phosphorylation and surface 
presence of spinal MORs. Insert: Animals were subcuta-
neously implanted with an oily morphine suspension (time 
zero). Subsequently, the development of tolerance was mon-
itored at various intervals post-opioid administration by 
measuring the analgesia produced by the release of the opi-
oid. Groups of 10 mice were sacrificed at different intervals 
and the dorsal horns of the cervical-dorsal spinal cords were 
removed. To analyze the phosphorylation and presence of 
MORs in the plasma membrane, the immunoprecipitation 
was performed under denaturing conditions. For every post-
opioid interval analyzed, densitometric signals associated 
with 55–65, 70–75, and 90–100 kDa were pooled and nor-
malized to those obtained probing the anti-MOR IgGs (heavy 
chain). The assay was repeated twice and the results were 
comparable. Further details as in Fig. 1.
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The coupling of plasma membrane MORs to G proteins redu es tolerance to opioidsFig r  7
The coupling of plasma membrane MORs to G pro-
teins reduces tolerance to opioids. The mice were icv-
injected with one or two doses of 10 nmol morphine spaced 
6 h apart, or they received a single icv dose of 200 pmol 
DAMGO. Groups of mice that had received the same opioid 
treatment were sacrificed at various intervals post-opioid 
administration. The control mice received icv saline instead 
of the opioid treatment. The PAG synaptosomes (P2) and 
supernatant (S3) were obtained and the variations in the sur-
face and internalized MORs (representative data in Figs 1-3), 
and in the association of surface MORs with Gαi2 subunits, 
was analyzed (see data in Fig. 6). The densitometric signals 
corresponding to MORs and the associated Gαi2 subunits 
that were observed in PAG from control mice injected with 
saline alone were attributed an arbitrary value of 1. The 
MOR and Gαi2 values corresponding to mice killed at the 
post-opioid intervals studied were then normalized to the 
levels observed for the controls. After normalization of the 
data, the levels of surface MORs observed at the different 
post-opioid intervals were correlated with the co-precipita-
tion with Gαi2 subunits, as well as with the levels of internal-
ized MORs. Regression lines, regression coefficients and 
their confidence intervals of 95% are shown (Sigmaplot v10/
Sigmastat v 3.5). The data were pooled from two independ-
ent assays.
Opioid-induced transfer of Gα subunits to RGSZ2 and RGS9 proteinsFigure 6
Opioid-induced transfer of Gα subunits to RGSZ2 
and RGS9 proteins. Groups of 6 to 8 mice, icv-injected 
with 10 nmol morphine or 100 pmol DAMGO, were sacri-
ficed at different intervals post-opioid administration. Their 
PAG P2 fractions were then obtained and solubilized under 
nondenaturing conditions. The MOR, RGSZ2 and RGS9 pro-
teins were immunoprecipitated with specific antibodies from 
different aliquots of the same solubilized material. The pres-
ence of Gαi2 subunits was then analyzed in Western blots in 
which equal loading was verified by probing anti-MOR or 
anti-RGSZ2 IgGs in parallel blots using the same immunopre-
cipitated material. The data corresponding to the co-precipi-
tation of MORs or RGSZ2 with Gαi2 subunits were then 
normalized and are shown as the mean ± SEM from three 
determinations (two for RGS9 and Gαi2) performed in dif-
ferent PAG samples.
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more evident when the effect of the second dose of mor-
phine was studied, decreasing rapidly until the interval
between doses reached about 6 h. Longer intervals did not
increase desensitization and the analgesic activity of mor-
phine is progressively restored after 3 or 4 days [28]. These
observations coincide with the notion that DAMGO and
morphine produce low and high tolerance respectively.
However, the delayed tolerance to an acute dose of opioid
that operates in nervous tissue is known as single-dose tol-
erance [1], and this phenomenon is probably related to
the permanent transfer of Gα subunits to a subset of sign-
aling proteins specific to this tissue.
There is convincing evidence that relates the ability of
DAMGO to promote the Ser375 phosphorylation, inter-
nalization and recycling of MORs with its weak desensitiz-
ing capacity. Accordingly, when morphine promotes Ser-
phosphorylation and internalization of MORs in cells
[8,11,32], weak MOR desensitization develops [8,13]. In
our experimental paradigm, the second dose of 10 nmol
morphine spaced 6 h from the first promoted about one
third of the analgesic effects of the first dose, coupled with
intense phosphorylation and recycling of the MORs. The
reduced antinociceptive effects of this second dose of
morphine were relatively well reproduced by subsequent
administrations of this same dose of morphine but spaced
24 h apart (present work; [33]). Thus, resensitization of
MORs in neurons also requires the recovery of active
receptors in the cell membrane. This can be achieved by
de novo synthesis, although MOR turnover in the brain
takes several days [28,29]. Alternatively, and much more
rapidly resensitization may occur through the dephos-
phorylation and recycling of the internalized MORs to the
plasma membrane. While the first situation would corre-
spond to the recovery from the first morphine dose, the
second applies to the recovery from DAMGO administra-
tion or from a second dose of morphine given at least 6 h
after the first. Therefore, the use of agonists such as
DAMGO could be associated with a reasonable risk of
producing tolerance given that the MORs belong to the
class of GPCRs that are rapidly dephosphorylated and
recycled after internalization, [12,34]. Nevertheless, a
fraction of these internalized receptors are sorted to lyso-
somes and undergo proteolytic degradation [9]. Thus, the
repeated administration of DAMGO or morphine could
finally desensitize MORs, as observed after administering
three consecutives doses of these opioids. It could be
argued that agonists that attain their response by activat-
ing only a small fraction of MORs would be preferred for
the control of severe pain. However, it must be born in
mind when used in demanding protocols, these agonists
deplete the surface MORs before the novo synthesis can
restore the system, which also leads to inescapable desen-
sitization ([2,35,36], present study). Interestingly, even in
the demanding protocol used here, the effects that remain
after the third dose of morphine or DAMGO were fairly
well reproduced by a fourth dose given 18 h later. Obvi-
ously, it is difficult to extrapolate this observation to what
it is required to effectively drive opioid consumption.
However, the biological effects that these opioids con-
serve after their repeated administration could control
physical dependence and therefore, be responsible for the
craving behavior.
Morphine is a representative of a particular class of opioid
agonists that are useful as analgesics but that are associ-
ated with the risk of producing strong tolerance. The lim-
ited capacity of morphine to stimulate both Ser375
phosphorylation and MOR internalization could be due
to its high off rate from the activated MOR. Thus, mor-
phine will not remain bound to the receptors for long,
thereby reducing the probability of GRK phosphorylation
and/or the subsequent binding of β-arrestin to the ago-
nist-activated MOR to initiate internalization. The MORs
expressed in HEK 293 cells elude internalization upon
exposure to morphine, even if the opioid is incubated for
long periods of time at high concentrations [32]. The
receptors remain at the cell surface and since G protein
coupling is essential to increase their affinity towards ago-
nists but not to antagonists, then phosphorylation and
uncoupling from G proteins probably desensitizes MORs
[8]. In contrast, the MORs present in embryonic cultured
neurons were internalized upon incubation with mor-
phine [18]. While an acute dose of morphine produces
desensitization without the loss of surface receptors ([14],
present study), the administration of subsequent doses or
continuous administration promotes the phosphoryla-
tion and internalization of MORs. Therefore, these obser-
vations again indicate that different processes regulate
MOR activity in mature neurons.
One of such process transfers the control of opioid-acti-
vated Gα subunits from the MOR to certain RGS proteins.
The internalization of the MORs provokes the return of
most of these Gα subunits to re-constitute the G proteins
and resensitize the response to the agonist when they
again come under the control of the recycled receptors.
However, long-lasting transfer (sequestering) of MOR-
activated Gα subunits occurs when the effects of mor-
phine reach a certain level [21]. This phenomenon is
mediated by proteins of the RGS-R7/Rz subfamilies,
among which RGS9 and RGSZ2 are particularly relevant
[22,33]. This more persistent interaction seems to be facil-
itated by post-translational modifications of these RGS
proteins, permitting them to bind to the activated Gα sub-
units but precluding their GAP activity on them. Among
such modifications, the phosphorylation of serine resi-
dues in the RGS domain of RGS-R7 proteins and the ensu-
ing binding to 14-3-3 proteins appear to be highlyPage 9 of 13
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sequences in the RGS of RGS-Rz proteins [22]. The consol-
idation of this transfer is time-dependent and is probably
mediated by the action of certain kinases. Interestingly,
PKC has been implicated in MOR desensitization to mor-
phine, but little in the effects of DAMGO [37]. Moreover,
the antagonists of NMDA receptors reduce the develop-
ment of tolerance to morphine antinociception but have
little effect on that promoted by DAMGO [38]. Thus, the
sequestering of morphine-activated Gα subunits at RGS
proteins could involve the activation of glutamate NMDA
receptors, probably via PKC [39]. Further efforts will focus
on characterizing these mechanisms responsible for the
more resolute transfer of morphine-activated Gα subunits
to the RGS proteins.
As consequence of impeding the return of GαGDP subu-
nits would be the accumulation of free Gβγ dimers in the
environment of the MOR and the improved access of
GRKs. Thus, another dose of morphine will promote GRK
phosphorylation of the activated MORs. The internaliza-
tion of MORs produces a reduction in agonist signaling
and thus, this RGS-mediated mechanism would exert only
a minor effect. Hence, to diminish the signaling of ago-
nists that promote little or no internalization of MORs
(e.g. morphine), neural cells would sequester Gα subu-
nits. In this way, the impact of agonist signaling would be
reduced and the GRK phosphorylation of MORs would
also increase. The influence of such events depends not
only on the effect promoted by morphine but also on the
interval elapsed after the initial administration of the opi-
oid [21]. This characteristic could explain why delayed
tolerance is only observed when a second dose of mor-
phine is injected within a certain time interval. It could
also account for the limited desensitization observed for
DAMGO when a second dose was administered 24 h after
the first, and no before. At this late interval, moderate
sequestering of Gα subunits by RGSZ2 proteins could be
consolidated and might provoke the reduction in the anti-
nociceptive response to DAMGO. Mice with reduced lev-
els of RGS9 proteins display both an increase in the
analgesic effects of morphine and a poorer single-dose tol-
erance. Therefore, neural MORs can be regulated at the Gα
subunit level, as well as through the associated RGS pro-
teins. Hence, opioid resensitization not only requires
MOR internalization but also that the recycled receptors
recover control of the G proteins. This knowledge can be
complemented with the possibility of delaying the devel-
opment of tolerance, or even rescuing the system, by
influencing regulatory mechanisms that only operate in
mature neurons and in which a subset of signaling pro-
teins participates.
Conclusion
This study shows that neural cells have developed specific
mechanisms to control GPCR function when the agonists
are poor inducers of receptor internalization. Thus, toler-
ance to morphine in mature neurons develops through a
two step process. Firstly, MORs become depleted of Gα
subunits and they develop strong antinociceptive toler-
ance. Subsequently, additional doses of this agonist pro-
voke the phosphorylation and recycling of the MORs,
with the consequence that the effects that remain after the
first dose now desensitized at a much slower rate. Agonists
such as DAMGO that only activate a small fraction of
MORs to attain high levels of analgesia could be the
rational choice to control of severe pain. However, it must
be born in mind that when they are used in demanding
protocols, these agonists deplete the surface MORs before
the novo synthesis can replenish the system, leading inev-
itably to desensitization. These findings may be valuable
when considering therapies in which rotation of opioids
are considered.
Methods
Preparation of membranes from neural cells and 
subcellular fractionation
In these studies, male albino CD-1 mice weighing 22–25
g were used (Charles River, Barcelona, Spain). PAG synap-
tosomal membranes were obtained from groups of 6 to
10 mice that were sacrificed by decapitation at various
intervals after receiving an icv-injection of DAMGO or
morphine. The PAGs were collected and homogenized in
10 volumes of 25 mM Tris-HCl (pH 7.4), 1 mM EGTA and
0.32 M sucrose supplemented with a phosphatase inhibi-
tor mixture (Sigma # P2850), H89 (Sigma, B1427) and a
protease inhibitor cocktail (Sigma, P8340), that con-
tained 4-(2-aminoethyl)-benzenesulfonyl fluoride
(AEBSF), pepstatin A, transepoxysuccinyl-L-leucyla-
mido(4-guanidino)butane (E-64), bebstatin, leupeptin
and aprotinin. The homogenate was centrifuged at 1000 g
for 10 min to remove the nuclear fraction, pellet 1 (P1).
The supernatant (S1) was centrifuged at 20000 g for 20
min to obtain the crude synaptosomal pellet (P2). The
pellet (P2) was resuspended in buffer and centrifuged at
20000 g for an additional 20 min, and the final pellet was
diluted in Tris buffer supplemented with a mixture of pro-
tease inhibitors (0.2 mM phenilmethylsulphonyl fluo-
ride, 2 µg/mL leupeptin and 0.5 µg/mL aprotinin) before
aliquoting and freezing. The supernatant (S2) was centri-
fuged at 105,000 g for 1 h to obtain the crude microsomal
pellet (P3) (Beckman XL-70 ultracentrifuge, rotor Type 70
ti). The S3 supernatant was concentrated in Amicon Ultra-
4 centrifugal filter devices (nominal molecular weigh
limit NMWL of 10,000 #UFC8 01024, Millipore Iberica
S.A., Madrid, Spain), and it was then loaded on a 10–40%
continuous sucrose gradient and centrifuged at 225,000 g
for 18 h [[40] and references therein]. Ten 4 mL fractionsPage 10 of 13
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immunoprecipitated and analyzed by Western blotting.
Immunoprecipitation of MORs and the co-precipitation of 
signaling proteins
To evaluate the presence of MORs in the plasma mem-
brane and in intracellular structures the existing protein
interactions were disrupted under denaturing conditions
prior to performing immunoprecipitation. Thus, the PAG
synaptosomal membranes (P2) and supernatants (S3)
were heated in 40 mM Tris-HCl, 1% SDS buffer for 10 min
at 100°C in the presence of 2-mercaptoethanol. This mix-
ture was then cooled to room temperature and the SDS
concentration reduced 7-fold by adding octylthiogluco-
side to a final concentration of 20 mM, and the immuno-
precipitation of MOR was then performed with
biotinylated IgGs (Pierce #21217 & 21339) as described
below.
The co-precipitation of signaling proteins with the MORs,
RGSZ2 and RGS9 proteins was performed under non-
denaturing conditions. PAG preparations were sonicated
(2 cycles of 5 s each in 400 µL of buffer containing 50 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1% Nonidet P-40, and
50 µL protease and phosphatase inhibitors and H89). The
supernatant was cleared by incubating with 20 µL of
streptavidin-agarose (Sigma S1638) pre-equilibrated for 1
h at 4°C, which was recovered by centrifugation at 3000 g
for 5 min. The Nonidet P-40 solubilized proteins were
incubated overnight at 4°C with about 3 µg of affinity
purified biotinylated IgGs directed against the target pro-
tein. The immunocomplexes were recovered with strepta-
vidin agarose and the agarose pellets obtained by
centrifugation were washed three times, pelleted and
resuspended in Nonidet P-40 buffer. The resuspended
immunocomplexes were transferred to centrifugal filter
devices (5 µm, Amicon Microcon UFC40SV, Millipore)
and the Nonidet P-40 buffer was separated from the IgG-
agarose complexes by mild centrifugation. This washing
step was repeated twice before the agarose-immunocom-
plexes retained in the filter membrane were heated in Tris-
HCl pH 7,5, 1% SDS buffer at 100°C to separate the IgG-
agarose from the target proteins. The immunoprecipitated
proteins were then recovered by centrifugation and con-
centrated in centrifugal filter devices (10,000 kDa nomi-
nal molecular weight limit, Amicon Microcon YM-10
#42407, Millipore), solubilized in 2 × Laemmli buffer and
resolved by SDS-PAGE. The detached anti MOR IgGs
retained in the filter membrane were used to normalize
the MOR-related signals. This procedure yielded enough
protein to load four to six gel lanes. The proteins were
transferred to 0.2 µm polyvinylidene difluoride mem-
branes (PVDF; Amersham Biosciences, Spain) and probed
with the selected antibodies in DecaProbe chambers (PR
150, Hoefer-AmershamBiosciences, Barcelona, Spain).
The procedures used to prepare the PAG enriched synap-
tosomes, supernatant and the pull-down experiments
have been described in detail elsewhere [21,22].
Detection of signaling proteins
Western blots were probed with a series of antibodies
raised against signaling proteins. The blots were probed
with affinity purified IgGs: antibodies directed against
peptide sequences in the murine MOR1 (diluted 1:1000):
NT (DSSAGPGNISDCSDP, residues 2–16 of the extracel-
lular N-terminal [25]), 2EL (TKYRQGSID, 208–216 of the
second external loop [25]), anti Gαi2 (1:1000, [25]); anti-
β-arrestin2 (1:1000, Calbiochem 178600); anti-C-Raf
(1:2000, BD Transduction labs., 610151). Rabbit polyclo-
nal IgGs against phospho-µ-opioid receptor (Ser375)
(1:1000, Cell Signaling, 3451) were used to analyze the
phosphorylation state of the MORs. All the antibodies
were diluted in TBS + 0.05% Tween 20 (TTBS) and incu-
bated with the PVDF membranes for 24 h at 6°C. The pri-
mary antibodies were detected with the corresponding
secondary antibodies conjugated to horseradish peroxi-
dase diluted 1:10000 in TTBS. Antibody binding was vis-
ualized with the ECL+plus Western Blotting Detection
System (RPN2132, Amersham Biosciences) and the
chemiluminescence was recorded with a ChemiImager IS-
5500 (Alpha Innotech, San Leandro, California)
equipped with a Peltier cooled CCD camera that provided
a real time readout of 30 frames per second (-35°C; high
signal-to-noise ratio; dynamic range up of 3.4 OD). Den-
sitometry was performed using Quantity One Software
(BioRad) and expressed as the mean ± S.E. of the inte-
grated volume (average optical density of the pixels
within the object area/mm2). For each treatment, the
assays were typically performed twice or three times on
samples obtained from independent groups of mice and
the results were comparable. For assays in which the
immunoprecipitated protein was modified by the opioid
treatment, equal loading was verified and where necessary
the signal adjusted using that obtained when detecting the
heavy chain of the IgGs used to precipitate the target pro-
tein. The IgGs present in the immunoprecipitated samples
were detached from the target proteins and processed in
parallel gels/blots [21].
Animals, intracerebroventricular injection and evaluation 
of antinociception
Male albino CD-1 mice weighing 22–25 g were housed
and handled in accordance with the European Commu-
nity guidelines for the Care and Use of Laboratory Ani-
mals (Council Directive 86/609/EEC). Animals were
lightly anaesthetized with ether, and the opioids were
injected into the lateral ventricle in a volume of 4 µL, as
described previously [41]. The response of the animals to
nociceptive stimuli was determined by the warm water
(52°C) tail-flick test. Latencies in seconds were deter-Page 11 of 13
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after the administration of the substance under study (test
latency). Baseline latencies ranged from 1.5 to 2.2 seconds
and a cut-off time of 10 seconds was allotted to minimize
the risk of tissue damage. Antinociception was expressed
as the percentage of the maximum possible effect (MPE =
100 × [test latency-baseline latency]/[cut-off time-base-
line latency]).
Induction and assessment of tolerance upon continuous 
morphine treatment
Groups of 15–20 mice were subcutaneously (sc)
implanted with 10 ml/kg body weight of a suspension
containing 50% saline (0.9% NaCl in distilled water),
42.5% mineral oil (Sigma #400-5), 7.5% mannide
monooleate (Sigma #M-8546), and 0.1 g/ml morphine
base. The oily pellet offers an animal model of opioid tol-
erance-dependence that reproduces the rapid rise of mor-
phine in serum and brain described for hard pellets [30].
Development of tolerance was monitored by measuring
the analgesic response promoted by the release of the opi-
oid.
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